The advantages of percutaneous core needle biopsy in evaluating breast abnormalities are well documented. For lesions that are clinically consistent with benign abnormalities such as fibroadenoma, surgical interventions may be avoided, and for clinically suspicious lesions, needle biopsy is an efficient strategy for establishing a breast cancer diagnosis nonoperatively. In the latter scenario, diagnostic needle biopsy then permits the patient and physician to proceed with planning of definitive breast and axillary staging surgery within a single initial operative experience. Furthermore, diagnostic needle biopsy prior to attempted breast-conserving surgery has been shown to improve success rates with margin negativity and smaller-volume lumpectomy.
1,2 Percutaneous core needle biopsy as a breast evaluation strategy can be particularly valuable and effective in facilities that have high prevalence of advanced-stage breast cancer, such as those located in underdeveloped nations. The bulky breast tumor is more likely to have a diagnostic needle biopsy, with minimal risk of sampling error. Facilities that have limited financial resources will also benefit from implementing a rapid, office-or clinicbased biopsy maneuver that promotes more efficient utilization of operating room resources. Lastly, the healthcare of medically underserved patients in underdeveloped countries is enhanced by opportunities to streamline clinic visits and cancer treatment planning. The present study describes the impact of a training program in percutaneous core needle biopsy implemented in conjunction with a breast cancer research collaboration between the University of Michigan and the Komfo Anokye Teaching Hospital, Kumasi, Ghana.
METHODS
The University of Michigan (UM) has collaborated with the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana for the study of breast cancer in women with African ancestry as part of an institutional review board (IRB)-approved program since June 2006. When this partnership was initiated, the primary definitive diagnostic intervention for women evaluated at KATH involved surgical incisional or excisional biopsy. In July 2007 a training program for performance of core needle biopsy was jointly coordinated by the UM and KATH principal investigators (L.N. and B.A.) for this research program. Participants included KATH medical staff involved with clinical care of breast patients, KATH pathology technicians, and KATH breast clinic nursing staff. The program involved a didactic session followed by observation of core needle biopsies performed by an experienced surgical breast oncologist (L.N.) and culminated with hands-on performance of core needle biopsies by KATH medical staff on KATH breast clinic patients after obtaining informed consent. The entire training course required less than 1 week for implementation. The KATH team (led by B.A.) identified seven patients with highly suspicious, palpable breast abnormalities for participation. These cases were all discussed in the KATH multidisciplinary tumor board meeting, which was attended by members of the surgery service, pathology, medical oncology, and radiation oncology. The UM principal investigator (PI) (L.N.) provided a didactic discussion regarding the advantages and technique of percutaneous core needle biopsy during one of the KATH breast clinic sessions, as well as during this multidisciplinary tumor board meeting. The observational and hands-on biopsy program was then conducted in the KATH breast clinic facility. The UM PI (L.N.) performed the percutaneous core needle biopsy on the initial patient, and the KATH participants as well as the UM PI performed the core needle biopsies on the remaining six patients, supervised by the UM PI. A minimum of three core needle passes were performed on each of the six patients, to maximize tissue yield and minimize sampling error.
We report herein the patterns of breast biopsies and pathology results at KATH after the implementation of this training program. All of the core needle biopsies at KATH (during and following the training session) were performed on palpable breast masses using 14-16-gauge spring-loaded core needle biopsy devices featuring a 10-20-cm throw/core extraction length. A selection of these biopsy materials obtained via core biopsies and via surgical biopsies was evaluated by dedicated breast pathologists at UM in an effort to assess reporting concordance. Additional histologic features and molecular marker features were evaluated by the University of Michigan team, as immunohistochemistry technology for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)/neu markers is not currently available at KATH. Details regarding the study of these markers are reported in the context of another report. 3 
RESULTS
Following the core needle biopsy training course (July 2007 through August 2008), 82 core needle biopsies of breast masses were performed at KATH. There were no cases of significant hematoma (requiring evacuation) or major infections (requiring hospitalization or intravenous antibiotics) complicating any of these procedures. A median of three (range 2-5) core specimen passes were performed per patient.
Of the total sample, 56 had tissue specimens available for review at the University of Michigan for comparison with KATH primary pathology reports.
Forty-six of the 56 UM-reviewed cases (82%) had a KATH diagnosis of breast cancer, and the UM pathology review was in agreement with the cancer diagnosis in all 46 cases (100%). Clinicopathologic features for the cancer cases (as per the University of Michigan pathology review) are shown in Table 1 . Approximately two-thirds were invasive ductal carcinomas, and 80% were grade 3 lesions. Seventy-six percent of the cancers were ER negative, and two-thirds were negative for ER, PR, and HER2/neu (triple negative).
Ten of the 56 UM-reviewed cases (18%) had a KATH diagnosis of benign fibroadenoma/fibrocystic breast tissue, and the UM review was concordant in all ten cases (100% concordance for benign lesions). For the remaining 26 core needle biopsy procedures we were unable to retrieve either the KATH pathology report or tissue blocks for UM review. The limited financial resources at KATH preclude maintenance of a formal tumor registry with cancer case ascertainment and data extraction. Inconsistencies in medical record identifiers therefore resulted in these several cases where tumor blocks and medical record information could not be definitively and reliably matched.
DISCUSSION
The 21st century is an era where the appropriate biopsy maneuver for a breast cancer patient is critical for planning optimal and comprehensive treatment. An initial diagnostic needle biopsy is rapid and cost efficient (compared with surgical diagnostic biopsy), and since measureable disease will remain following utilization of this procedure, it preserves the option of neoadjuvant systemic therapy for selected patients. Core needle biopsy is generally preferred over fine needle aspiration biopsy, because of the generally lower sampling error associated with the former and because of the larger volume of tissue retrieved, making it possible for the pathologist to document invasive versus in situ disease and to grade the tumor accurately. Immunohistochemical assays for the three standard molecular markers utilized in breast cancer (estrogen receptor, progesterone receptor, and HER2/neu) are critical for determining appropriate adjuvant systemic therapy options, and these markers are more reliably obtained with core needle biopsy as well. Although immunohistochemistry can indeed be performed on cytology specimens, it is impossible to determine whether the evaluated markers are from the invasive tumor cells or the in situ component, and it is the marker panel from the invasive cancer that determines treatment recommendations. Patients with tumors that are positive for the estrogen receptor and/or the progesterone receptor will be candidates for endocrine therapy, while patients with tumors that overexpress HER2/neu will be candidates for trastuzumab therapy. Lastly, node-negative and estrogen-receptor-positive breast cancer patients will be eligible for genetic profiling to determine their 21-gene recurrence score (OncotypeDx), and this information may also guide decisions regarding adjuvant chemotherapy in addition to endocrine therapy. [4] [5] [6] Furthermore, it is now well established that breast cancer is a disease comprising several different tumor subtypes that are characterized by varying degrees of malignant potential. The molecular marker panel can provide a surrogate classification schema for identifying these subtypes. For example, the basal breast cancer subtype is generally perceived as being a particularly aggressive and virulent pattern, and most of these tumors are identified as the ''triple-negative'' breast cancers that are negative for expression of the estrogen, progesterone, and HER2/neu markers. The study of breast cancer disparities has led to increased appreciation for race/ethnicity-associated variation in prevalence of breast cancer subtypes. Most notably, women with African ancestry (African as well as AfricanAmerican) have significantly higher frequency of estrogenreceptor-negative and triple-negative/basal breast cancer subtypes. [7] [8] [9] [10] [11] The molecular marker patterns of this Ghanaian breast cancer subset were consistent with our findings from a larger comparative analysis involving Ghanaian, African-American, and White-American cases. 3 Studies of breast cancer burden among developing nations of Africa will therefore become increasingly important as we seek to understand the genetics of basal breast tumors, and as we try to identify markers that may be useful for prevention and/or treatment. Industrialized and developed nations therefore have an obligation to share best practices and improved diagnostic technology with developing nations because it is ''the right thing to do'' and also because these partnerships can promote valuable research opportunities regarding the pathogenesis of high-risk breast cancer.
For these reasons, we hypothesized that a training program in percutaneous core needle biopsies would be a valuable system for the breast oncology program at KATH in Kumasi, Ghana. Ghana is located on the western, subSaharan coast of Africa. It has been an independent country, with a democratically elected government and English as its official language, since 1957. It has an estimated population of 18,412,247 (females 51%, males 49%), resulting in an overall population density of 201 persons per square mile. The most densely populated parts of the country are the coastal areas, the Ashanti region, and the two principal cities, Accra and Kumasi. KATH is located in Kumasi, which is the capital city for the Ashanti region of Ghana and has a population of more than 1.5 million. Ghana is widely acknowledged to be one of the most economically and politically stable countries in Africa, however with an unemployment rate of 20% and nearly one-third of its population living below the international poverty line of US$ 1.25 per day, it is clearly underdeveloped in comparison with more affluent Western populations. The Ghanaian population is clearly medically underserved, with approximately 15 physicians and 93 nurses per 100,000 persons, and life expectancy of 59 years for men and 60 years for women. 12, 13 Globocan International estimates breast cancer incidence and mortality rates to be approximately 24.8 and 11.3 per 100,000 population, respectively.
14 However the imprecision of these rates must be emphasized because of suboptimal data collection regarding cancer cases in undeveloped countries where tumor registries are nonexistent. The limited financial resources at KATH preclude maintenance of a centralized hospital-based cancer registry, however it is estimated that approximately 250 newly diagnosed breast cancer patients are evaluated annually, and that more than three-quarters of these patients have locally advanced disease. Because mammographic screening is not widely or uniformly available to the Ghanaian female population, the vast majority of breast cancer patients seen at KATH present with palpable, clinically overt disease. Percutaneous, free-hand needle biopsy represents the only alternative to surgical biopsy, because image guidance via mammography or breast ultrasound is not widely available. This procedure spares women from having to return to the hospital for diagnostic surgical biopsy, and it supports more efficient utilization of surgical suite services. Lastly, the collaborative relationship that grew as a consequence of conducting this training program strengthened the ongoing international breast cancer research program currently underway between the University of Michigan and the Komfo Anoyke Teaching Hospital.
A major limitation of our study is the fact that we do not have follow-up information on the benign needle biopsies, and so we cannot assess the false-negative rate. However the concept of sampling error associated with needle biopsy was strongly emphasized in the course of our training program, so that all participants were aware of the need to pursue additional surgical biopsy efforts if the needle biopsy result was discordant with the clinical impression.
As research involving breast cancer disparities expands in the direction of international work involving developing nations, it will become increasingly important to implement appropriate diagnostic biopsy programs. These programs must above all serve the purpose of accurately identifying and classifying breast cancer, and they should also be suitable for acquisition of tissue that can be banked for future diagnostic, treatment, and research needs. 15 Our study demonstrated that implementation of a 1-week training program in percutaneous core needle biopsy among a multidisciplinary group of physicians was well received and effective.
